Radioactive medical isotopes lead-203 (203Pb) and lead-212 (212Pb), which are compatible with nuclear imaging and cancer therapy, respectively, have recently gained international academic and commercial attention due to successes in clinical trials. Through initial imaging with 203Pb-labeled drugs, physicians can determine if the patient will be suitable for treatment with the 212Pb-labeled counterpart, allowing for […]
Read More